Pembrolizumab-induced nephrotoxicity in a patient with breast cancer

By sjmartinez • April 29, 2024

Alkassis S, Fitzsimmons K, Hurvitz S. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241248362. doi: 10.1177/17588359241248362. PMID: 38680292; PMCID: PMC11047248.

Tags: adverse event management, breast cancer, Checkpoint Inhibitor, Fellow, Hematology/Oncology, immune-related adverse events, immune-related adverse events < immunotherapy, immunotherapy, Publications

Cumulative burden of depression and domain-specific cognitive impairment over time in the women’s interagency HIV study: A marginal structural model approach

Tejera CH, Duggal P, Diaz M, Topper E, Gustafson D, Jamieson BD, Maki PM, Sharma A, Spence AB, Weber KM, Weinstein AM, Jones DL, Fazeli[...]

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis

Young AC, Andréasson K, Labus J, Matulionis N, Jacobs JP, Christofk H, Volkmann ER. Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis.[...]

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria[...]